MOLN vs. CRDL, SCLX, CLLS, DBVT, VXRT, OMGA, KPTI, OTLK, VCXB, and BCAB
Should you be buying Molecular Partners stock or one of its competitors? The main competitors of Molecular Partners include Cardiol Therapeutics (CRDL), Scilex (SCLX), Cellectis (CLLS), DBV Technologies (DBVT), Vaxart (VXRT), Omega Therapeutics (OMGA), Karyopharm Therapeutics (KPTI), Outlook Therapeutics (OTLK), 10X Capital Venture Acquisition Corp. III (VCXB), and BioAtla (BCAB). These companies are all part of the "medical" sector.
Molecular Partners (NASDAQ:MOLN) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends, community ranking and profitability.
Molecular Partners has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.
Cardiol Therapeutics received 3 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 50.00% of users gave Cardiol Therapeutics an outperform vote while only 44.00% of users gave Molecular Partners an outperform vote.
26.5% of Molecular Partners shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 5.9% of Molecular Partners shares are held by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Cardiol Therapeutics has a net margin of 0.00% compared to Molecular Partners' net margin of -885.11%. Molecular Partners' return on equity of -31.10% beat Cardiol Therapeutics' return on equity.
Cardiol Therapeutics has lower revenue, but higher earnings than Molecular Partners. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.
Molecular Partners presently has a consensus target price of $4.50, suggesting a potential upside of 21.59%. Cardiol Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 171.49%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Molecular Partners.
In the previous week, Molecular Partners and Molecular Partners both had 1 articles in the media. Cardiol Therapeutics' average media sentiment score of 1.87 beat Molecular Partners' score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.
Summary
Cardiol Therapeutics beats Molecular Partners on 11 of the 17 factors compared between the two stocks.
Get Molecular Partners News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Molecular Partners Competitors List
Related Companies and Tools
